

Yasuhiko Tomino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8468665/publications.pdf>

Version: 2024-02-01

75
papers

8,062
citations

172457
29
h-index

98798
67
g-index

76
all docs

76
docs citations

76
times ranked

6414
citing authors

#	ARTICLE	IF	CITATIONS
1	A case of hereditary angioedema due to C1-inhibitor deficiency with recurrent abdominal pain diagnosed 40 years after the occurrence of the initial symptom. Clinical Journal of Gastroenterology, 2021, 14, 1175-1179.	0.8	2
2	A grading system that predicts the risk of dialysis induction in IgA nephropathy patients based on the combination of the clinical and histological severity. Clinical and Experimental Nephrology, 2019, 23, 16-25.	1.6	18
3	Impacts of Indoxyl Sulfate and p-Cresol Sulfate on Chronic Kidney Disease and Mitigating Effects of AST-120. Toxins, 2018, 10, 367.	3.4	119
4	High doses of antipsychotic polypharmacy are related to an increase in serum levels of pentosidine in patients with schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 76, 42-48.	4.8	8
5	High serum soluble tumor necrosis factor receptor 1 predicts poor treatment response in acute-stage schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 76, 145-154.	4.8	11
6	Toll-Like Receptor 9 Stimulation Induces Aberrant Expression of a Proliferation-Inducing Ligand by Tonsillar Germinal Center B Cells in IgA Nephropathy. Journal of the American Society of Nephrology: JASN, 2017, 28, 1227-1238.	6.1	91
7	Diagnosis and treatment of patients with IgA nephropathy in Japan. Kidney Research and Clinical Practice, 2016, 35, 197-203.	2.2	29
8	Clinical decision support system for end-stage kidney disease risk estimation in IgA nephropathy patients. Nephrology Dialysis Transplantation, 2016, 31, 80-86.	0.7	38
9	Beyond the Differences in Tonsillectomy in IgA Nephropathy: From Rationale To Indications in Patients. , 2016, , 311-319.		0
10	The Prevalence and Management of Diabetic Nephropathy in Asia. Kidney Diseases (Basel, Switzerland), 2015, 1, 52-60.	2.5	48
11	Altered serum glyceraldehyde-derived advanced glycation end product (AGE) and soluble AGE receptor levels indicate carbonyl stress in patients with schizophrenia. Neuroscience Letters, 2015, 593, 51-55.	2.1	19
12	Role of the TNF pathway in the progression of diabetic nephropathy in KK-A ^y mice. American Journal of Physiology - Renal Physiology, 2014, 306, F1335-F1347.	2.7	65
13	Effect of AST-120 on Endothelial Dysfunction in Adenine-Induced Uremic Rats. International Journal of Nephrology, 2014, 2014, 1-8.	1.3	17
14	Serum levels of galactose-deficient immunoglobulin (Ig) A1 and related immune complex are associated with disease activity of IgA nephropathy. Clinical and Experimental Nephrology, 2014, 18, 770-777.	1.6	59
15	A Paradigm Shift for the Concept of Diabetic Nephropathy. Juntendo Medical Journal, 2014, 60, 293-299.	0.1	4
16	Effect of the Direct Renin Inhibitor Aliskiren on Urinary Albumin Excretion in Spontaneous Type 2 Diabetic KK- Mouse. International Journal of Nephrology, 2013, 2013, 1-10.	1.3	6
17	Association of the Cardioankle Vascular Index and Ankle-Brachial Index with Carotid Artery Intima Media Thickness in Hemodialysis Patients. International Journal of Nephrology, 2013, 2013, 1-5.	1.3	2
18	Transperitoneal Calcium Balance in Anuric Continuous Ambulatory Peritoneal Dialysis and Automated Peritoneal Dialysis Patients. International Journal of Nephrology, 2013, 2013, 1-5.	1.3	3

#	ARTICLE	IF	CITATIONS
19	Pathogenesis and Novel Treatment from the Mouse Model of Type 2 Diabetic Nephropathy. Scientific World Journal, The, 2013, 2013, 1-8.	2.1	26
20	Usefulness of Change in Estimated Glomerular Filtration Rate as a Predicting Factor of Progression of Chronic Kidney Disease. ISRN Nephrology, 2013, 2013, 1-6.	1.2	0
21	Pathological Scenario with the Mannose-Binding Lectin in Patients with IgA Nephropathy. Journal of Biomedicine and Biotechnology, 2012, 2012, 1-5.	3.0	14
22	Tonsillar TLR9 expression and efficacy of tonsillectomy with steroid pulse therapy in IgA nephropathy patients. Nephrology Dialysis Transplantation, 2012, 27, 1090-1097.	0.7	55
23	Experimental Models of Type-2 Diabetic Nephropathy. Experimental Diabetes Research, 2012, 2012, 1-2.	3.8	2
24	Effect of Exercise on Kidney Function, Oxidative Stress, and Inflammation in Type 2 Diabetic KK-AyMice. Experimental Diabetes Research, 2012, 2012, 1-10.	3.8	50
25	An analysis of functional activity via the three complement pathways during hemodialysis sessions: a new insight into the association between the lectin pathway and C5 activation. CKJ: Clinical Kidney Journal, 2012, 5, 401-404.	2.9	7
26	Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study. Modern Rheumatology, 2012, 22, 394-404.	1.8	77
27	Identification of quantitative trait loci for diabetic nephropathy in KK-Ay/Ta mice. Journal of Nephrology, 2012, 25, 127-136.	2.0	7
28	Efficacy of adsorbent in delaying dialysis initiation among chronic kidney disease patients. Dialysis and Transplantation, 2011, 40, 212-216.	0.2	6
29	Attenuating effect of angiotensin-(1-7) on angiotensin II-mediated NAD(P)H oxidase activation in type 2 diabetic nephropathy of KK-A ^y /Ta mice. American Journal of Physiology - Renal Physiology, 2011, 300, F1271-F1282.	2.7	78
30	Role of Mindin in Diabetic Nephropathy. Experimental Diabetes Research, 2011, 2011, 1-6.	3.8	11
31	Effect of Combination Therapy with Angiotensin Receptor Blocker and 1,25-Dihydroxyvitamin D ₃ in Type 2 Diabetic Nephropathy in KK-A ^y /Ta Mice. Nephron Experimental Nephrology, 2011, 117, e124-e132.	2.2	33
32	Mindin: a novel marker for podocyte injury in diabetic nephropathy. Nephrology Dialysis Transplantation, 2011, 26, 2153-2160.	0.7	31
33	Pathological Role of Tonsillar B Cells in IgA Nephropathy. Clinical and Developmental Immunology, 2011, 2011, 1-8.	3.3	34
34	Evidence of immunopathological traces in mucormycosis: an autopsy case. Clinical and Experimental Nephrology, 2010, 14, 396-400.	1.6	6
35	Combination Effects of Enalapril and Losartan on Lipid Peroxidation in the Kidneys of KK-A ^y /Ta Mice. Nephron Experimental Nephrology, 2009, 113, e66-e76.	2.2	21
36	Contribution of subcutaneous fat accumulation to insulin resistance and atherosclerosis in haemodialysis patients. Nephrology Dialysis Transplantation, 2009, 24, 3474-3480.	0.7	19

#	ARTICLE	IF	CITATIONS
37	Revised Equations for Estimated GFR From Serum Creatinine in Japan. American Journal of Kidney Diseases, 2009, 53, 982-992.	1.9	5,260
38	Tonsillectomy and steroid pulse (TSP) therapy for patients with IgA nephropathy: a nationwide survey of TSP therapy in Japan and an analysis of the predictive factors for resistance to TSP therapy. Clinical and Experimental Nephrology, 2009, 13, 460-466.	1.6	68
39	Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. Journal of Clinical Investigation, 2009, 119, 1668-77.	8.2	356
40	Effect of pitavastatin on type 2 diabetes mellitus nephropathy in KK-Ay/Ta mice. Metabolism: Clinical and Experimental, 2008, 57, 691-697.	3.4	29
41	Potential Immunopathogenic Role of the Mucosa-Bone Marrow Axis in IgA Nephropathy: Insights From Animal Models. Seminars in Nephrology, 2008, 28, 66-77.	1.6	43
42	Toll-Like Receptor 9 Affects Severity of IgA Nephropathy. Journal of the American Society of Nephrology: JASN, 2008, 19, 2384-2395.	6.1	160
43	IgA1-secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. Journal of Clinical Investigation, 2008, 118, 629-39.	8.2	217
44	Roles of Bone Marrow, Mucosa and Lymphoid Tissues in Pathogenesis of Murine IgA Nephropathy. , 2007, 157, 164-168.		9
45	Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-Ay/Ta mice. Metabolism: Clinical and Experimental, 2007, 56, 160-167.	3.4	85
46	Pathogenesis of IgA Nephropathy. , 2007, 157, 1-7.		15
47	Treatment for IgA Nephropathy. , 2007, 157, 8-12.		2
48	Hypercomplementemia in adult patients with IgA nephropathy. Journal of Clinical Laboratory Analysis, 2007, 21, 77-84.	2.1	39
49	Th2 cytokine induces aberrant O-glycosylation in the hinge region of IgA1 via downregulation of core1Î²1, 3-galactosyltransferase and its molecular chaperone Cosmc. JuntendoJ., Igaku, 2007, 53, 113-120.	0.1	0
50	Glomerular changes in the KK-Ay/Ta mouse: A possible model for human type 2 diabetic nephropathy. Nephrology, 2006, 11, 29-35.	1.6	61
51	Role of receptor for advanced glycation end-products and signalling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. Nephrology Dialysis Transplantation, 2006, 21, 299-313.	0.7	102
52	Eicosapentaenoic acid ameliorates diabetic nephropathy of type 2 diabetic KKAY/Ta mice: Involvement of MCP-1 suppression and decreased ERK1/2 and p38 phosphorylation. Nephrology Dialysis Transplantation, 2006, 21, 605-615.	0.7	79
53	A case of renal sarcoidosis with complement activation via the lectin pathway. American Journal of Kidney Diseases, 2005, 45, 580-587.	1.9	14
54	Pathogenesis and Treatment of Type 2 Diabetic Nephropathy: Lessons from the Spontaneous KK/Ta Mouse Model. Current Diabetes Reviews, 2005, 1, 281-286.	1.3	8

#	ARTICLE	IF	CITATIONS
55	Genome-Wide Scan in a Novel IgA Nephropathy Model Identifies a Susceptibility Locus on Murine Chromosome 10, in a Region Syntenic to Human IGAN1 on Chromosome 6q22â€“23. Journal of the American Society of Nephrology: JASN, 2005, 16, 1289-1299.	6.1	67
56	Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice. Nephrology Dialysis Transplantation, 2004, 19, 3012-3020.	0.7	94
57	Levels of urinary matrix metalloproteinaseâ€9 (MMPâ€9) and renal injuries in patients with type 2 diabetic nephropathy. Journal of Clinical Laboratory Analysis, 2004, 18, 206-210.	2.1	57
58	Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice. Metabolism: Clinical and Experimental, 2004, 53, 1473-1479.	3.4	60
59	Effects of candesartan, an angiotensin II type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice. Journal of Nephrology, 2003, 16, 841-9.	2.0	23
60	Effects of Oral Adsorbent AST-120 (Kremezin^{â„®}) on Renal Function and Glomerular Injury in Early-Stage Renal Failure of Subtotal Nephrectomized Rats. Nephron, 2002, 91, 480-485.	1.8	26
61	Asian multicenter trials on urinary type IV collagen in patients with diabetic nephropathy. Journal of Clinical Laboratory Analysis, 2001, 15, 188-192.	2.1	38
62	Effects of Automated Peritoneal Dialysis on Residual Urinary Volume. Peritoneal Dialysis International, 2000, 20, 239-241.	2.3	19
63	Usefulness of determining the plasma atrial natriuretic peptide(hANP) level in CAPD patients. Target plasma hANP levels for preventing left ventricular hyertrophy.. Nihon Toseki Igakkai Zasshi, 1998, 31, 913-917.	0.1	0
64	Significance of urinary type IV collagen in patients with diabetic nephropathy using a highly sensitive one-step sandwich enzyme immunoassay. Journal of Clinical Laboratory Analysis, 1997, 11, 110-116.	2.1	29
65	Value of pathological grading in prediction of renal survival in IgA nephropathy. Nephrology, 1996, 2, 107-117.	1.6	11
66	Altered steady-state levels of mrna coding for extracellular matrices in renal tissues of ddy mice, an animal model for iga nephropathy. Journal of Clinical Laboratory Analysis, 1991, 5, 106-113.	2.1	18
67	Computer Imaging Analysis of Glomerular Extracellular Components in Patients with IgA Nephropathy. Pathology International, 1989, 39, 296-305.	1.3	0
68	Detection of anionic sites and immunoglobulin a deposits in the glomerular capillary walls from patients with Iga nephropathy. Journal of Clinical Laboratory Analysis, 1989, 3, 101-107.	2.1	10
69	Detection of viral antigens in patients with IgA nephropathy.. Japanese Journal of Medicine, 1989, 28, 159-164.	0.1	12
70	Detection of platelets in urinary sediments from patients with â€œAdvancedâ€stages of immunoglobulin a nephropathy. Journal of Clinical Laboratory Analysis, 1988, 2, 241-244.	2.1	4
71	Clinical effect of danazol in patients with IgA nephropathy.. Japanese Journal of Medicine, 1987, 26, 162-166.	0.1	17
72	STUDIES ON GLOMERULAR IMMUNE SOLUBILIZATION BY COMPLEMENT IN PATIENTS WITH IgA NEPHROPATHY. Pathology International, 1987, 37, 1763-1767.	1.3	9

#	ARTICLE	IF	CITATIONS
73	EFFECT OF IMMUNOGLOBULIN DEPOSITION ON THE AMOUNT OF GLOMERULAR SIALIC ACIDS IN PATIENTS WITH MEMBRANOUS NEPHROPATHY. Pathology International, 1986, 36, 1807-1811.	1.3	1
74	DETECTION OF IMMUNOGLOBULINS AND OTHER SERUM PROTEINS IN THE DERMAL AND GLOMERULAR CAPILLARY WALLS FROM PATIENTS WITH DIABETES MELLITUS. Pathology International, 1986, 36, 1181-1189.	1.3	1
75	IMMUNOPATHOLOGICAL SIMILARITIES BETWEEN IgA NEPHROPATHY and HENOCH-SCHOENLEIN PURPURA (HSP) NEPHRITIS. Pathology International, 1983, 33, 113-122.	1.3	3